The potential use of thalidomide in the therapy of graft-versus-host disease—A review of clinical and laboratory information
- 31 December 1990
- journal article
- review article
- Published by Elsevier in Leukemia Research
- Vol. 14 (5) , 395-399
- https://doi.org/10.1016/0145-2126(90)90024-4
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- THALIDOMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDRENThe Lancet, 1988
- THALIDOMIDE FOR SEVERE ACUTE GRAFT-VERSUS-HOST DISEASEThe Lancet, 1988
- SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATIONThe Lancet, 1988
- Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for LeukemiaNew England Journal of Medicine, 1986
- Thalidomide: Use and possible mode of action in reactional lepromatous leprosy and in various other conditionsJournal of the American Academy of Dermatology, 1982
- TRANSPLANTATION FOR ACUTE LEUKAEMIA WITH HLA-A AND B NONIDENTICAL PARENTAL MARROW CELLS FRACTIONATED WITH SOYBEAN AGGLUTININ AND SHEEP RED BLOOD CELLSThe Lancet, 1981
- Effect of Thalidomide on the Graft versus Host ReactionNature, 1966
- ANOTHER CHANCE FOR THALIDOMIDEThe Lancet, 1966
- Prolongation of Skin Homograft Survival by ThalidomideBMJ, 1965
- EFFECT OF THALIDOMIDE ON SKIN-GRAFT SURVIVALThe Lancet, 1963